Consistently, dCas9-KRAB-sgG12S, but not LentiCas9-vector, treated tumor tissues exhibited markedly lower levels of both total and mutant KRAS proteins in A549-engrafted mice (Figure 5B). This evidence concerns the gene KRAS and neoplasm.